A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer

Kazuto Harada, Ahmed A.F. Abdelhakeem, Jaffer A. Ajani

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.

Original languageEnglish (US)
Pages (from-to)9-10
Number of pages2
JournalNature Reviews Clinical Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer'. Together they form a unique fingerprint.

Cite this